SCHEMBL186467

SCHEMBL186467

O=C(NC1(C(=O)NCc2ccc(Nc3ccc(F)cc3C(F)(F)F)cc2)CC1)c1cncs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.41
CNR2 P34972 2/20 0.39
CNR1 P21554 1/20 0.39
BDKRB1 P46663 2/20 0.39
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
PTK2 Q05397 1/20 0.35
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
AURKA O14965 3/20 0.34
P2RX7 Q99572 2/20 0.33
CHEK2 O96017 1/20 0.33
CSF1R P07333 1/20 0.33
RET P07949 1/20 0.33
FLT4 P35916 1/20 0.33
ABL2 P42684 1/20 0.33
BLK P51451 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2805738 0.92 AR (0.39) ARCNR2CNR1BDKRB1KMT2A
SCHEMBL13128425 0.86 BDKRB1 (0.48) CNR2CNR1BDKRB1ALDH1A1LMNA
SCHEMBL184742 0.83 CYP3A4 (0.40) CNR2CNR1BDKRB1ALDH1A1LMNA
SCHEMBL13128555 0.83 KMT2A (0.39) ARCNR2CNR1KMT2AP2RX7
SCHEMBL2806884 0.83 CNR2 (0.37) ARCNR2CNR1BDKRB1KMT2A
SCHEMBL2809661 0.83 AR (0.38) ARCNR2CNR1KMT2A
SCHEMBL2808499 0.82 ALDH1A1 (0.40) CNR2BDKRB1ALDH1A1LMNAAURKA
SCHEMBL185221 0.81 ALDH1A1 (0.38) CNR2CNR1BDKRB1ALDH1A1LMNA
SCHEMBL2805433 0.81 AR (0.38) ARCNR1BDKRB1
SCHEMBL185889 0.80 OPRL1 (0.38) ARCNR2BDKRB1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 US disclosed
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 US disclosed
EP-2401256-B1 Compounds as bradykinin B1 antagonists BOEHRINGER INGELHEIM INT (DE) 2013-04-17 EP disclosed
EP-2401256-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2012-01-04 EP disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
WO-2010097372-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 WO disclosed
WO-2010097372-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131075-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 AR 1452/4885CNR2 882/4885CNR1 211/4885
US-20100240669-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 AR 1452/4885CNR2 882/4885CNR1 211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.